TAT-11: Ac225-PSMA617 in Chemotherapy-naïve Patients with Advanced Prostate Cancer

Ottawa, ON, Canada (UroToday.com) In Africa, it is not unusual for patients to be diagnosed late in the disease progression so that alpha therapy is introduced directly after ADT with no prior chemotherapy. Dr. Sathekge described a clinical trial of 17 chemo-naïve patients treated with Ac225-PSMA617 in 2-month intervals starting with an initial dose of 8 MBq follow by de-escalation in 1 MBq steps. Patient progress was monitored by PSA levels and imaging with Ga68-PSMA PET imaging and dosing could be modified based on results. For example, one patient had an increased dose of 13 MBq. The therapy was quite effective with greater than 90% decline in 82% of patients. 41% of patients with undetectable PSA remained in remission for 12 months. Xerostomia was seen in all patients but none was so serious that treatment was stopped, likely due to the dose de-escalation.

Presented by Professor Mike Sathekge, MB ChB, MMed, Ph.D., FAMS, The University of Pretoria, Department of Nuclear Medicine

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada

Login